newsfilter
← Latest News
Business Wire·

QT Imaging Issues Mid-Year 2026 CEO Letter to Shareholders

QTI
  • QT Imaging Holdings, Inc. issued a mid-year 2026 shareholder letter from CEO Dr. Raluca Dinu highlighting significant progress in commercial, clinical, regulatory, & operational areas.
  • The company generated $14.0 million in revenue for the first half of 2026, representing a 116% year-over-year increase, with 28 Breast Acoustic CT scanners shipped.
  • More than 12,000 women have now been imaged using the Breast Acoustic CT modality, providing extensive real-world clinical experience.
  • QT Imaging returned to the Nasdaq Capital Market, was added to the Russell Microcap® Index, completed a $10 million public offering, & extended its senior secured term loan maturity to March 31, 2029.
  • Cash & restricted cash stood at approximately $14.2 million as of August 7, 2026, enhancing financial flexibility for continued growth.
  • The company secured two FDA clearances for enhanced scanner configurations & software supporting volumetric measurements, & passed its first routine FDA inspection with zero Form 483 observations.
  • International regulatory progress includes authorizations in Saudi Arabia, the UAE, & Israel, alongside distribution partnerships with Gulf Medical, Al Naghi Medical, & Re-Invent Pharma.
  • A Category III CPT code for 3D quantitative transmission volumetric ultrasound tomography of the breast was approved by the AMA on July 1, 2026, becoming effective January 1, 2027.
  • New leadership appointments include Dr. Julia Albright as Chief Science Officer & regional sales leaders to strengthen the direct U.S. commercial organization.
  • QT Imaging relocated its headquarters & manufacturing operations to a new 22,000-square-foot facility in Petaluma, California, increasing operational space by 2.5x while reducing lease costs by approximately 55%.
  • Clinical evidence programs are advancing, including studies at Mayo Clinic, Sunnybrook Breast Cancer Program, & Rambam Health Care Campus to evaluate diagnostic performance & quantitative biomarkers.
  • The company is developing the QT Imaging Precision Pathway cloud platform with collaborations involving Olea Medical & Intelerad for advanced data management & AI-enabled analysis.
  • Priorities for the second half of 2026 include accelerating commercial adoption, expanding clinical evidence, broadening global market access, advancing platform innovation, & scaling operational capacity.
  • Full-year 2026 revenue guidance remains at approximately $39 million, reflecting a trajectory of strong commercial scaling from $0 in 2023, $4.9 million in 2024, & $18.9 million in 2025.